23.14
-0.27 (-1.13%)
| Previous Close | 23.41 |
| Open | 23.72 |
| Volume | 33,263 |
| Avg. Volume (3M) | 94,724 |
| Market Cap | 453,809,760 |
| Price / Earnings (TTM) | 72.31 |
| Price / Earnings (Forward) | 66.23 |
| Price / Sales | 10.50 |
| Price / Book | 7.03 |
| 52 Weeks Range | |
| Earnings Date | 11 Mar 2026 |
| Profit Margin | 9.01% |
| Operating Margin (TTM) | 4.99% |
| Diluted EPS (TTM) | 0.220 |
| Quarterly Revenue Growth (YOY) | 26.80% |
| Quarterly Earnings Growth (YOY) | 897.30% |
| Total Debt/Equity (MRQ) | 8.73% |
| Current Ratio (MRQ) | 5.03 |
| Operating Cash Flow (TTM) | 12.13 M |
| Levered Free Cash Flow (TTM) | 3.66 M |
| Return on Assets (TTM) | 1.42% |
| Return on Equity (TTM) | 7.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Brainsway Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 6.40% |
| % Held by Institutions | 32.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Valor Management Llc | 31 Dec 2025 | 2,657,475 |
| Huntleigh Advisors, Inc. | 31 Dec 2025 | 87,076 |
| 52 Weeks Range | ||
| Median | 30.00 (29.65%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Jan 2026 | 30.00 (29.65%) | Buy | 12.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Jan 2026 | Announcement | BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™ |
| 12 Jan 2026 | Announcement | BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD) |
| 07 Jan 2026 | Announcement | BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™ |
| 22 Dec 2025 | Announcement | BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™ |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |